In: Journal of Antimicrobial Chemotherapy, 2017, vol. 72, no. 4, p. 1089-1093
|
In: Journal of Antimicrobial Chemotherapy, ///-
|
In: European Journal of Clinical Microbiology & Infectious Diseases, 2015, vol. 34, no. 10, p. 1937-1945
|
In: Amino Acids, 2015, vol. 47, no. 4, p. 693-705
|
In: Journal of Antimicrobial Chemotherapy, 2017, vol. 72, no. 11, p. 3070-3078
|
In: International Journal of Antimicrobial Agents, 2020, vol. 56, no. 6, p. 106157
Background: Carbapenemase-producing Gram-negative bacteria cause infections that are difficult to treat and represent a rising threat to healthcare systems worldwide. This study analysed isolates of Escherichia coli (E. coli), a species associated with nosocomial-acquired and community-acquired infections, from hospitals in Germany and Switzerland exhibiting a slight decrease in...
|
In: Journal of Clinical Microbiology, 2020, p. -
A series of clinical NDM-5-producing E. coli isolates obtained from two surveillance networks of carbapenem-producing Enterobacterales from 2018-2019, namely Switzerland (NARA) and Germany (SurvCARE), were analyzed. The 33 NDM-5- producing E. coli isolates were highly resistant to β-lactams including the novel ß- lactam/ß-lactamase inhibitor combinations (ceftazidime/avibactam, ...
|
In: Microbial Drug Resistance, 2020, p. -
Objectives: To evaluate the biochemical Rapid ESBL NP® (Liofilchem, Italy) for the rapid detection of extended-spectrum β-lactamases (ESBLs) in Enterobacterales.Methods: A total of 100 clinical gram-negative strains (40 ESBL producers with or without cephalosporinase, 43 carbapenemase producers with or without additional ESBLs, 8 AmpC-type producers, 6 penicillinase producers, and 3 ...
|
In: Antimicrobial Agents and Chemotherapy, 2020, vol. 64, no. 2020-12, p. -
Metallo-β-lactamase (MBL)-producing Escherichia coli isolates resistant to the newly developed β-lactam/β-lactamase inhibitor drug combination aztreonam-avibactam (ATM-AVI) have been reported. Here, we analyzed a series of 118 clinical MBL- producing E. coli isolates of various geographical origins for susceptibility to ATM-AVI. The nature of the PBP3 protein sequence and the occurrence of...
|
In: Journal of Antimicrobial Chemotherapy, 2020, vol. 75, no. 12, p. 3593–3600
Background: Carbapenemase-producing Enterobacterales represent a major therapeutic challenge. MBLs, requiring zinc at their catalytic site, could be inhibited by meso-dimercaptosuccinic acid (DMSA), a heavy metal chelator already widely used for treating lead intoxication.Objectives: To evaluate the activity of carbapenems alone or combined with DMSA against MBL-producing Escherichia coli in...
|